Retour

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stocks Changes in company's own shares

WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra’s independent directors serving on its Compensation Committee and granted under Lyra’s 2022 Employment Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewswire Inc. • 26/04/2024 à 22:51:00
Lyra Therapeutics, Inc. Common Stock
Address: 480 ARSENAL WAY
Postal Code: 02472
City: WATERTOWN
State: MA
Phone Number: 617-373-4600
Website: https://lyratherapeutics.com
Status: Active
Company Info

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

List Date2020-05-01
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001327273
Composite figiBBG001J2N202
Share Class figiBBG001V0GBW5
Market Cap245,688,382 USD
SIC Code3841
SIC DescriptionSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Total Employees109
Share Class Shares Outstanding60970000
Weighted Shares Outstanding60964859
Round Lot100
Updated date2024-05-05
Stats
Last 5 days
7-05
6-05
3-05
2-05
1-05
Last
0.409
0.502
4.195
4.805
5.28
Variance
-17.87%
-88.33%
-12.7%
-8.46%
2.33%
Open
0.498
4.3
4.805
5.249
5.16
Highest
0.517
4.3
4.805
5.249
5.595
Lowest
0.516
4.3
4.805
5.23
5.593
History
PeriodVarhighestlowest
1 week
-92.29%
5.595
0.449
1 month
-92.22%
6.409
0.449
3 month
-92.15%
5.07
0.449
6 month
-86.73%
3.13
0.449
1 year
-84.69%
2.7
0.449
3 year
-95.26%
8.48
0.449
5 year
-98.1%
22
0.449
10 year
-98.1%
22
0.449
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-08 2023-11-07 UNPUB
Assets 93,868,000 125,675,000 120,575,000 UNPUB
Current Assets 84,799,000 118,253,000 104,920,000 UNPUB
Current Liabilities 14,154,000 14,111,000 19,235,000 UNPUB
Equity 66,091,000 98,577,000 84,239,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 66,091,000 98,577,000 84,239,000 UNPUB
Liabilities 27,777,000 27,098,000 36,336,000 UNPUB
Liabilities And Equity 93,868,000 125,675,000 120,575,000 UNPUB
Noncurrent Assets 9,069,000 7,422,000 15,655,000 UNPUB
Noncurrent Liabilities 13,623,000 12,987,000 17,101,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-08 2023-11-07 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -10,531,000 32,342,000 -29,511,000 UNPUB
Net Cash Flow, Continuing -10,531,000 32,342,000 -29,511,000 UNPUB
Net Cash Flow From Financing Activities 4,000 47,185,000 -418,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 4,000 47,185,000 -418,000 UNPUB
Net Cash Flow From Investing Activities 5,315,000 -561,000 -14,979,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 5,315,000 -561,000 -14,979,000 UNPUB
Net Cash Flow From Operating Activities -15,850,000 -14,282,000 -14,114,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -15,850,000 -14,282,000 -14,114,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-08 2023-11-07 UNPUB
Comprehensive Income/Loss -16,277,000 -15,633,000 -15,631,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -16,277,000 -15,633,000 -15,631,000 UNPUB
Other Comprehensive Income/Loss -22,000 -15,633,000 -15,631,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-08 2023-11-07 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 16,651,000 16,064,000 16,179,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 16,651,000 16,064,000 16,179,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,255,000 -15,618,000 -15,651,000 UNPUB
Income/Loss From Continuing Operations Before Tax -16,241,000 -15,606,000 -15,635,000 UNPUB
Income Tax Expense/Benefit 14,000 12,000 16,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,255,000 -15,618,000 -15,651,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -16,255,000 -15,618,000 -15,651,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -16,255,000 -15,618,000 -15,651,000 UNPUB
Operating Expenses 17,723,000 16,961,000 17,371,000 UNPUB
Operating Income/Loss -17,313,000 -16,503,000 -16,827,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 410,000 458,000 544,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-08 2023-03-29
Assets 47,345,000 130,035,000 119,463,000 109,968,000
Current Assets 40,555,000 122,381,000 112,230,000 100,829,000
Current Liabilities 17,802,000 9,872,000 13,605,000 14,470,000
Equity 23,257,000 106,249,000 93,222,000 80,754,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 23,257,000 106,249,000 93,222,000 80,754,000
Liabilities 19,189,000 19,005,000 26,241,000 29,214,000
Liabilities And Equity 47,345,000 130,035,000 119,463,000 109,968,000
Noncurrent Assets 6,790,000 7,654,000 7,233,000 9,139,000
Noncurrent Liabilities 0 0 12,636,000 14,744,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-08 2023-03-29
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -11,992,000 88,003,000 -11,111,000 -12,134,000
Net Cash Flow, Continuing -11,992,000 88,003,000 -11,111,000 -12,134,000
Net Cash Flow From Financing Activities 6,000 96,487,000 -236,000 96,257,000
Net Cash Flow From Financing Activities, Continuing 6,000 96,487,000 -236,000 96,257,000
Net Cash Flow From Investing Activities -93,000 -14,000 -29,000 -65,006,000
Net Cash Flow From Investing Activities, Continuing -93,000 -14,000 -29,000 -65,006,000
Net Cash Flow From Operating Activities -11,905,000 -8,470,000 -10,846,000 -43,385,000
Net Cash Flow From Operating Activities, Continuing -11,905,000 -8,470,000 -10,846,000 -43,385,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-08 2023-03-29
Comprehensive Income/Loss -11,911,000 -14,366,000 -14,766,000 -55,268,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,012,000 -14,484,000 -14,766,000 -55,268,000
Other Comprehensive Income/Loss 0 0 -14,766,000 10,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-08 2023-03-29
Basic Earnings Per Share UNPUB UNPUB 0 -2
Benefits Costs and Expenses 12,379,000 0 0 56,628,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 12,379,000 14,925,000 15,185,000 56,628,000
Diluted Earnings Per Share UNPUB UNPUB 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -11,911,000 -14,366,000 -14,766,000 -55,278,000
Income/Loss From Continuing Operations Before Tax -11,911,000 -14,366,000 359,000 -55,265,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 13,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,012,000 -14,366,000 -14,766,000 -55,278,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -11,911,000 -14,366,000 -14,766,000 -55,278,000
Net Income/Loss Available To Common Stockholders, Basic -11,911,000 -14,366,000 -14,766,000 -55,278,000
Operating Expenses 12,393,000 14,925,000 15,185,000 57,669,000
Operating Income/Loss -7,026,000 -14,518,000 -14,826,000 -56,306,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 5,367,000 407,000 359,000 1,363,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-09 2021-11-09 2022-03-09
Assets 72,917,000 76,332,000 67,762,000 54,867,000
Current Assets 67,351,000 70,073,000 60,886,000 47,918,000
Current Liabilities 4,170,000 5,904,000 17,773,000 18,246,000
Equity 67,551,000 57,499,000 47,188,000 34,316,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 67,551,000 57,499,000 47,188,000 34,316,000
Liabilities 5,366,000 18,833,000 20,574,000 20,551,000
Liabilities And Equity 72,917,000 76,332,000 67,762,000 54,867,000
Noncurrent Assets 5,566,000 6,259,000 6,876,000 6,949,000
Noncurrent Liabilities 0 0 2,801,000 2,305,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-09 2021-11-09 2022-03-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -8,488,000 2,941,000 -10,915,000 -28,846,000
Net Cash Flow, Continuing -8,488,000 2,941,000 -10,915,000 -28,846,000
Net Cash Flow From Financing Activities 262,000 185,000 -84,000 359,000
Net Cash Flow From Financing Activities, Continuing 262,000 185,000 -84,000 359,000
Net Cash Flow From Investing Activities -1,160,000 -625,000 -517,000 -3,385,000
Net Cash Flow From Investing Activities, Continuing -1,160,000 -625,000 -517,000 -3,385,000
Net Cash Flow From Operating Activities -7,590,000 3,381,000 -10,314,000 -25,820,000
Net Cash Flow From Operating Activities, Continuing -7,590,000 3,381,000 -10,314,000 -25,820,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-09 2021-11-09 2022-03-09
Comprehensive Income/Loss -7,802,000 -11,039,000 -11,055,000 -43,513,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,802,000 -11,039,000 -11,055,000 -43,513,000
Other Comprehensive Income/Loss 0 -11,039,000 -11,055,000 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-09 2021-11-09 2022-03-09
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB 0 43,798,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 11,095,000 43,798,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,802,000 -11,039,000 -11,055,000 -43,513,000
Income/Loss From Continuing Operations Before Tax -7,802,000 -11,039,000 14,000 -43,513,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,802,000 -11,039,000 -11,055,000 -43,513,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,802,000 -11,039,000 -11,055,000 -43,513,000
Net Income/Loss Available To Common Stockholders, Basic -7,802,000 -11,039,000 -11,055,000 -43,513,000
Operating Expenses 7,831,000 11,065,000 11,095,000 43,900,000
Operating Income/Loss -7,831,000 -11,065,000 -11,081,000 -43,615,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 14,000 285,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2020-08-05 2020-11-10 2021-03-09
Assets UNPUB 92,723,000 87,330,000 80,830,000
Current Assets UNPUB 89,310,000 83,555,000 75,917,000
Current Liabilities UNPUB 3,942,000 4,708,000 4,884,000
Equity UNPUB 86,823,000 80,914,000 74,492,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 86,823,000 80,914,000 74,492,000
Liabilities UNPUB 5,900,000 6,416,000 6,338,000
Liabilities And Equity UNPUB 92,723,000 87,330,000 80,830,000
Noncurrent Assets UNPUB 3,413,000 3,775,000 4,913,000
Noncurrent Liabilities UNPUB 0 1,708,000 1,454,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2020-08-05 2020-11-10 2021-03-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB 51,352,000 -5,044,000 64,785,000
Net Cash Flow, Continuing UNPUB 51,352,000 -5,044,000 64,785,000
Net Cash Flow From Financing Activities UNPUB 58,907,000 -675,000 87,703,000
Net Cash Flow From Financing Activities, Continuing UNPUB 58,907,000 -675,000 87,703,000
Net Cash Flow From Investing Activities UNPUB -77,000 -589,000 -1,775,000
Net Cash Flow From Investing Activities, Continuing UNPUB -77,000 -589,000 -1,775,000
Net Cash Flow From Operating Activities UNPUB -7,478,000 -3,780,000 -21,143,000
Net Cash Flow From Operating Activities, Continuing UNPUB -7,478,000 -3,780,000 -21,143,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2020-08-05 2020-11-10 2021-03-09
Comprehensive Income/Loss UNPUB -4,540,000 -6,334,000 -22,127,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -4,540,000 -6,334,000 -22,127,000
Other Comprehensive Income/Loss UNPUB -4,540,000 -6,334,000 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2020-08-05 2020-11-10 2021-03-09
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -4,540,000 -6,334,000 -22,127,000
Income/Loss From Continuing Operations Before Tax UNPUB -4,540,000 -6,334,000 -22,127,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB -4,540,000 -6,334,000 -22,127,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -4,540,000 -6,334,000 -22,127,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -4,570,000 -6,334,000 -22,242,000
Operating Expenses UNPUB 4,545,000 6,363,000 22,209,000
Operating Income/Loss UNPUB -4,545,000 -6,363,000 -22,209,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 30,000 0 115,000
Preferred Stock Dividends And Other Adjustments UNPUB 30,000 0 115,000
Revenues UNPUB 0 0 0
Calendar
8 May 2024 (Time UTC) Actual Previous Consensus
★
13:30
United States
★
13:00
United States
4.560
★
12:00
United States
★
11:45
United States
★
11:00
United States
★
11:00
United States
MAY
53.440
★
10:30
United States
MAY 03
915000.000
344000.000
-1180000.000
★
10:30
United States
MAY 03
1.000
-1.000
★
10:30
United States
MAY 03
285000.000
-179000.000
★
10:30
United States
MAY 03
99000.000
254000.000
★
10:30
United States
MAY 03
560000.000
-732000.000
-1000000.000
★
10:30
United States
275000.000
-271000.000
★★
10:30
United States
MAY 03
1880000.000
1089000.000
★
10:30
United States
MAY 03
-353000.000
1536000.000
★
10:30
United States
MAY 03
307000.000
-230000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:LYRA240419C00002500 OCASPS Call American 100 2.5 EMLD 2024-04-19
O:LYRA240419P00010000 OPASPS Put American 100 10 EMLD 2024-04-19
O:LYRA240419C00010000 OCASPS Call American 100 10 EMLD 2024-04-19
O:LYRA240419P00007500 OPASPS Put American 100 7.5 EMLD 2024-04-19
O:LYRA240419P00005000 OPASPS Put American 100 5 EMLD 2024-04-19
O:LYRA240419P00002500 OPASPS Put American 100 2.5 EMLD 2024-04-19
O:LYRA240419C00007500 OCASPS Call American 100 7.5 EMLD 2024-04-19
O:LYRA240419C00005000 OCASPS Call American 100 5 EMLD 2024-04-19
O:LYRA240315P00010000 OPASPS Put American 100 10 EMLD 2024-03-15
O:LYRA240315P00007500 OPASPS Put American 100 7.5 EMLD 2024-03-15
O:LYRA240315P00005000 OPASPS Put American 100 5 EMLD 2024-03-15
O:LYRA240315P00002500 OPASPS Put American 100 2.5 EMLD 2024-03-15
O:LYRA240315C00010000 OCASPS Call American 100 10 EMLD 2024-03-15
O:LYRA240315C00007500 OCASPS Call American 100 7.5 EMLD 2024-03-15
O:LYRA240315C00005000 OCASPS Call American 100 5 EMLD 2024-03-15
O:LYRA240315C00002500 OCASPS Call American 100 2.5 EMLD 2024-03-15
O:LYRA240216P00007500 OPASPS Put American 100 7.5 EMLD 2024-02-16
O:LYRA240216P00005000 OPASPS Put American 100 5 EMLD 2024-02-16
O:LYRA240216P00002500 OPASPS Put American 100 2.5 EMLD 2024-02-16
O:LYRA240216C00007500 OCASPS Call American 100 7.5 EMLD 2024-02-16
O:LYRA240216C00005000 OCASPS Call American 100 5 EMLD 2024-02-16
O:LYRA240216C00002500 OCASPS Call American 100 2.5 EMLD 2024-02-16
O:LYRA240119P00007500 OPASPS Put American 100 7.5 EMLD 2024-01-19
O:LYRA240119P00005000 OPASPS Put American 100 5 EMLD 2024-01-19
O:LYRA240119P00002500 OPASPS Put American 100 2.5 EMLD 2024-01-19
O:LYRA240119C00007500 OCASPS Call American 100 7.5 EMLD 2024-01-19
O:LYRA240119C00005000 OCASPS Call American 100 5 EMLD 2024-01-19
O:LYRA240119C00002500 OCASPS Call American 100 2.5 EMLD 2024-01-19
O:LYRA231215P00007500 OPASPS Put American 100 7.5 EMLD 2023-12-15
O:LYRA231215P00005000 OPASPS Put American 100 5 EMLD 2023-12-15
O:LYRA231215P00002500 OPASPS Put American 100 2.5 EMLD 2023-12-15
O:LYRA231215C00007500 OCASPS Call American 100 7.5 EMLD 2023-12-15
O:LYRA231215C00005000 OCASPS Call American 100 5 EMLD 2023-12-15
O:LYRA231215C00002500 OCASPS Call American 100 2.5 EMLD 2023-12-15
O:LYRA231117P00010000 OPASPS Put American 100 10 EMLD 2023-11-17
O:LYRA231117P00007500 OPASPS Put American 100 7.5 EMLD 2023-11-17
O:LYRA231117P00005000 OPASPS Put American 100 5 EMLD 2023-11-17
O:LYRA231117P00002500 OPASPS Put American 100 2.5 EMLD 2023-11-17
O:LYRA231117C00010000 OCASPS Call American 100 10 EMLD 2023-11-17
O:LYRA231117C00007500 OCASPS Call American 100 7.5 EMLD 2023-11-17
O:LYRA231117C00005000 OCASPS Call American 100 5 EMLD 2023-11-17
O:LYRA231117C00002500 OCASPS Call American 100 2.5 EMLD 2023-11-17
O:LYRA231020P00007500 OPASPS Put American 100 7.5 EMLD 2023-10-20
O:LYRA231020P00005000 OPASPS Put American 100 5 EMLD 2023-10-20
O:LYRA231020P00002500 OPASPS Put American 100 2.5 EMLD 2023-10-20
O:LYRA231020C00007500 OCASPS Call American 100 7.5 EMLD 2023-10-20
O:LYRA231020C00005000 OCASPS Call American 100 5 EMLD 2023-10-20
O:LYRA231020C00002500 OCASPS Call American 100 2.5 EMLD 2023-10-20
O:LYRA230915P00007500 OPASPS Put American 100 7.5 EMLD 2023-09-15
O:LYRA230915P00005000 OPASPS Put American 100 5 EMLD 2023-09-15
O:LYRA230915P00002500 OPASPS Put American 100 2.5 EMLD 2023-09-15
O:LYRA230915C00007500 OCASPS Call American 100 7.5 EMLD 2023-09-15
O:LYRA230915C00005000 OCASPS Call American 100 5 EMLD 2023-09-15
O:LYRA230915C00002500 OCASPS Call American 100 2.5 EMLD 2023-09-15
O:LYRA230818P00007500 OPASPS Put American 100 7.5 EMLD 2023-08-18
O:LYRA230818P00005000 OPASPS Put American 100 5 EMLD 2023-08-18
O:LYRA230818P00002500 OPASPS Put American 100 2.5 EMLD 2023-08-18
O:LYRA230818C00007500 OCASPS Call American 100 7.5 EMLD 2023-08-18
O:LYRA230818C00005000 OCASPS Call American 100 5 EMLD 2023-08-18
O:LYRA230818C00002500 OCASPS Call American 100 2.5 EMLD 2023-08-18
News Stream
Stocks Changes in company's own shares
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra’s independent directors serving on its Compensation Committee and granted under Lyra’s 2022 Employment Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 1w ago
News News
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks Investment Research • 1mo ago
News News
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research • 1mo ago
stocks News
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research • 1mo ago
News News
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • 1mo ago
Stocks Earnings Releases and Operating Results
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
GlobeNewswire Inc. • 1mo ago
News News
Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks Investment Research • 2mo ago
Stocks Changes in company's own shares
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra. The employment inducement awards were approved by Lyra’s independent directors serving on its Compensation Committee and granted under the Company’s 2022 Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 2mo ago
News News
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research • 2mo ago
News News
Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Lyra Therapeutics, Inc. (LYRA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT